Hospital
Pulaski Community Hospital INC
Pulaski Community Hospital INC was paid $14.29M by Medicaid between Jan 2018 and Dec 2024, across 175 billing codes. Its largest line is 99283, emergency room visit (moderate) — 29% of everything it billed.
33Billing provider infoPULASKI COMMUNITY HOSPITAL INC
PULASKI, VA 24301
PULASKI, VA 24301
33aNPI1205882396assigned 05/26/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$14.29M
24GClaims408,631
24DCodes billed175
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#42 of 80
Median peer was paid$14.69M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 48,200 | $1.01M | |
| 2019 | 65,240 | $1.94M | |
| 2020 | 58,965 | $1.69M | |
| 2021 | 57,203 | $1.78M | |
| 2022 | 62,529 | $2.48M | |
| 2023 | 66,707 | $2.93M | |
| 2024incomplete | 49,787 | $2.46M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 29% | 26,170 | 22,125 | $4.12M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 16,605 | 13,445 | $2.36M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.8% | 7,571 | 6,862 | $1.25M |
| 96361 | Intravenous infusion, hydration; each additional hour | 8.3% | 5,177 | 4,208 | $1.19M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.8% | 4,672 | 3,798 | $683K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.7% | 3,527 | 3,093 | $675K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.8% | 3,497 | 2,895 | $540K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.0% | 1,638 | 1,542 | $290K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.0% | 1,786 | 1,528 | $285K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 5,768 | 4,692 | $209K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.4% | 552 | 496 | $204K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 2,780 | 2,149 | $201K |
163 more codes
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.3% | 5,356 | $193K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.1% | 2,275 | $157K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.1% | 5,522 | $152K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,021 | $138K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,941 | $130K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 537 | $120K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,648 | $103K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 503 | $96K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 415 | $94K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,287 | $93K |
| 80053 | Comprehensive metabolic panel | <1% | 21,152 | $67K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,972 | $62K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,072 | $59K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 663 | $57K |
| 77336 | <1% | 890 | $54K | |
| G0378 | Hospital observation service, per hour | <1% | 1,282 | $47K |
| 77386 | <1% | 222 | $46K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 66 | $41K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 11,289 | $39K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,282 | $38K |
| 77412 | <1% | 136 | $37K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,889 | $34K |
| 87400 | <1% | 8,129 | $28K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 565 | $24K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,600 | $22K |
| 85027 | <1% | 27,529 | $21K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,347 | $20K |
| 87040 | <1% | 4,493 | $18K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 674 | $17K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,160 | $17K |
| 83880 | <1% | 3,461 | $16K | |
| 97161 | <1% | 428 | $15K | |
| 72110 | <1% | 780 | $14K | |
| 73564 | <1% | 1,227 | $13K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 682 | $13K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,117 | $12K |
| 84484 | <1% | 8,182 | $8K | |
| 73030 | <1% | 802 | $8K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 347 | $7K |
| 73630 | <1% | 1,141 | $7K | |
| 85379 | <1% | 1,955 | $7K | |
| 80047 | <1% | 1,552 | $6K | |
| 73610 | <1% | 839 | $6K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,147 | $6K |
| 12001 | <1% | 24 | $6K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 59 | $6K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 571 | $5K |
| 84703 | <1% | 3,250 | $5K | |
| 84439 | <1% | 1,208 | $5K | |
| 85018 | <1% | 1,206 | $4K | |
| 90715 | <1% | 252 | $4K | |
| 81001 | <1% | 10,320 | $4K | |
| 83605 | <1% | 3,898 | $4K | |
| 93971 | <1% | 51 | $4K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,470 | $3K |
| 73130 | <1% | 579 | $3K | |
| 80076 | <1% | 1,460 | $3K | |
| 87420 | <1% | 817 | $3K | |
| 85610 | <1% | 4,461 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,251 | $3K |
| 87088 | <1% | 3,207 | $3K | |
| 77300 | <1% | 52 | $3K | |
| 83735 | <1% | 6,992 | $3K | |
| 71250 | <1% | 27 | $2K | |
| 82728 | <1% | 387 | $2K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 4,301 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,278 | $2K |
| 73110 | <1% | 366 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,282 | $2K |
| 86140 | <1% | 1,025 | $2K | |
| 96376 | <1% | 831 | $2K | |
| 74018 | <1% | 137 | $2K | |
| 81025 | <1% | 3,733 | $2K | |
| 83690 | <1% | 6,108 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,267 | $1K |
| 76641 | <1% | 13 | $1K | |
| 72100 | <1% | 43 | $1K | |
| 83550 | <1% | 332 | $1K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 6,598 | $1K |
| 84100 | <1% | 3,536 | $996.88 | |
| 71271 | <1% | 12 | $952.75 | |
| 87070 | <1% | 3,937 | $893.25 | |
| 82607 | <1% | 101 | $834.88 | |
| 73502 | <1% | 85 | $824.05 | |
| 81003 | <1% | 5,994 | $796.64 | |
| 83540 | <1% | 370 | $796.02 | |
| 96367 | <1% | 16 | $759.58 | |
| 10060 | <1% | 19 | $750.00 | |
| 87077 | <1% | 2,465 | $695.75 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 560 | $694.53 |
| 71101 | <1% | 54 | $642.87 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 195 | $526.32 |
| 80061 | Lipid panel | <1% | 176 | $517.45 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 360 | $495.73 |
| 87186 | <1% | 1,381 | $427.22 | |
| 87430 | <1% | 3,981 | $403.71 | |
| 82746 | <1% | 85 | $383.16 | |
| 74022 | <1% | 97 | $381.59 | |
| 85652 | <1% | 294 | $325.71 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,882 | $302.34 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,157 | $288.92 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 562 | $278.43 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 21 | $275.82 |
| 83090 | <1% | 55 | $267.28 | |
| 85730 | <1% | 2,110 | $264.04 | |
| 80305 | <1% | 959 | $236.55 | |
| 83615 | <1% | 159 | $234.68 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,463 | $229.78 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 41 | $204.66 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,303 | $185.87 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 1,951 | $168.02 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,659 | $146.03 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 791 | $141.18 |
| 83921 | <1% | 29 | $138.59 | |
| 85045 | <1% | 87 | $133.48 | |
| 73590 | <1% | 16 | $130.46 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,802 | $130.25 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,651 | $129.09 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 756 | $126.27 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,961 | $125.83 |
| 82805 | <1% | 427 | $115.97 | |
| 80074 | <1% | 30 | $73.75 | |
| 73080 | <1% | 13 | $69.51 | |
| 72072 | <1% | 12 | $69.28 | |
| 87205 | <1% | 206 | $62.13 | |
| 74021 | <1% | 13 | $56.31 | |
| 82248 | <1% | 56 | $55.29 | |
| 85014 | <1% | 123 | $54.67 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 151 | $50.96 |
| 82565 | <1% | 17 | $44.83 | |
| A9270 | Non-covered item or service | <1% | 5,507 | $40.53 |
| J1815 | Injection, insulin, per 5 units | <1% | 733 | $39.11 |
| 86618 | <1% | 42 | $35.25 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,310 | $33.04 |
| 87147 | <1% | 261 | $32.86 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 577 | $32.69 |
| 82550 | <1% | 146 | $32.33 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 600 | $31.88 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 372 | $31.58 |
| 87210 | <1% | 61 | $27.98 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 287 | $23.55 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 681 | $21.92 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 272 | $14.54 |
| 86900 | <1% | 46 | $9.02 | |
| 96368 | <1% | 13 | $6.91 | |
| 86901 | <1% | 46 | $5.93 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 393 | $4.94 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 41 | $0.46 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 103 | $0.44 |
| J3490 | Unclassified drugs | <1% | 1,757 | $0.13 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 15 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 41 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 232 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 73 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 62 | $0.00 |
| Q0169 | Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 39 | $0.00 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 38 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 42 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 349 | $0.00 |
| 82803 | 0% | 50 | $0.00 | |
| G1011 | Clinical decision support mechanism, qualified tool not otherwise specified, as defined by the medicare appropriate use criteria program | 0% | 12 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 14 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 59 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSTANTON, RACHAEL (CFO)
| Provider | Location | Paid |
|---|---|---|
| Montgomery Regional Hospital INC | Blacksburg, VA | $17.14M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.